SiBionics
SiBionics is a Shenzhen-based medical device company developing factory-calibrated continuous glucose, ketone, and AI screening sensors, selling direct-to-consumer and to hospitals across 86+ countries with 2M+ cumulative users.
- Company typePrivate
- Founded2015
- HeadquartersShenzhen, China
- Headcount501–1,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What SiBionics does
SiBionics (硅基仿生) is a Shenzhen-headquartered medical device company founded in 2015 that designs, manufactures, and commercializes continuous monitoring products for chronic disease management. Its core technology is a proprietary second-generation electrochemical sensor based on metal redox polymers, which supports factory-calibrated sensing without finger-prick calibration and is embodied in the GS1 and GS3 continuous glucose monitors (CGM), with MARD 8.83% on GS1 and a 2.9mm/1.5g form factor on GS3. The company has extended the platform into the KS3 continuous ketone monitor — described as the world's first commercialized CKM — and is developing a combined glucose-ketone (CGKM) system currently in China's National Innovative Medical Device Special Review Program. Adjacent product lines include the eye-si (爱昔瞳) AI fundus screening device, the RPS60 artificial retina in clinical trials, a capsule endoscopy robot, the SiDoctor patient app, and a digital hospital-wide blood glucose management system deployed across Chinese hospitals.
The company sells through a hybrid direct-to-consumer e-commerce channel and a B2B hospital channel, with sensors priced 30–40% below international incumbents. SiBionics holds NMPA, EU CE MDR, FDA registration, and MDSAP (US/Australia/Brazil/Canada) certifications, has more than 265 invention patents, and operates with 700+ employees (40%+ in R&D) and an annual production capacity exceeding 1.2 million units in partnership with Flex. Commercial reach spans 86+ countries, 70+ authorization agreements, 3,900+ medical institutions, 800+ hospitals in China, and 700+ Chinese cities, with a cumulative user base of more than 2 million and approximately 200,000 active users as of EASD 2025. Channel partners include Novo Nordisk (Digital Health Ecosystem Partnership Alliance, November 2025) and ProMedEx (exclusive Saudi Arabia distribution, February 2025).
SiBionics firmographics
Firmographics- Name
- SiBionics
- Legal name
- 深圳硅基仿生科技股份有限公司
- Website
- https://sibionics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- SiBionics is a Shenzhen-based medical device company developing factory-calibrated continuous glucose, ketone, and AI screening sensors, selling direct-to-consumer and to hospitals across 86+ countries with 2M+ cumulative users.
- Ownership category
- akta.pro rank
SiBionics industry classification
Industry- Product category
- Continuous Glucose Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Industrial Instruments For Measurement, Display, And Control (3823)
- akta.pro primary industry
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)
- akta.pro secondary industries
- Diabetes (General) (HLAKADAA), Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)
Keywords
Where SiBionics is headquartered
LocationHeadquarters
- HQ city
- Shenzhen
- HQ country
- China
- HQ region
- Asia
Offices6 records
Markets served
SiBionics business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- CGM device hardware sales: Sale of disposable CGM sensors and reusable transmitters to individual consumers (direct-to-consumer via e-commerce) and to hospitals/institutional buyers (enterprise sales). Primary revenue driver, with sensors providing recurring revenue from each 14-day sensor cycle and transmitters providing durable goods revenue.
- Hospital/institutional blood glucose management solutions: Digital hospital-wide blood glucose management system sold to hospitals, enabling multi-department patient monitoring, remote endocrinology consultation, and integration with hospital HIS systems. Revenue includes both software/platform licensing and hardware components.
- Internet hospital and digital health services: AI-powered diagnostic and chronic disease management services through the company's internet hospital platform, including professional report interpretation, dietary counseling, and personalized health management services bundled with CGM device purchases.
- International market sales: Revenue from international markets via CE MDR and MDSAP certifications, selling CGM devices through local distributors and partnerships in over 70 countries, with targeted expansion into Europe, Latin America, Middle East, and Southeast Asia.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | GS1 CGM priced 30-40% below competitors |
| Unit Pricing | Pay-as-you-go | GS1 reusable transmitter + disposable probes (分体式复用设计) |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels7 records
SiBionics product offering
Product offeringCore offering
SiBionics develops, manufactures, and sells continuous glucose monitoring (CGM) systems using proprietary second-generation electrochemical sensor technology with metal redox polymer electron mediators. The company sells CGM sensors, reusable transmitters, hospital-wide blood glucose management platforms, AI fundus screening software (eye-si), and is commercializing the world's first continuous ketone monitoring (KS3 CKM) system, serving both individual consumers and healthcare institutions across 70+ countries.
Product overview
SiBionics是一家专注于慢病管理的医疗器械企业，采用平台+产品组合架构。核心产品线包括持续葡萄糖监测系统（硅基动感GS1/GS3 CGM、硅基轻享）和持续酮体监测系统（KS3 CKM），结合数字化全院血糖管理平台和硅基互联网医院提供从监测到诊疗的完整服务。AI产品线包括爱昔瞳眼底AI筛查系统，辅助诊断20余种眼底病变。创新在研产品包括人工视网膜和胶囊胃镜机器人。子公司硅基传感、硅基算力分别聚焦CGM传感器工艺和胰岛素数字疗法/闭环算法研发。
Differentiator
Problem solved
Functional benefit
Brands
- 硅基动感: Continuous Glucose Monitoring (CGM) system brand, includes GS1, GS3 CGM products
- SIBIONICS CGM
- 硅基轻享
- 爱昔瞳 (eye-si)
- 硅基医生 (SiDoctor)
- 贝塔俱乐部 (Beta Club)
- SiFree控糖营
- SIBIO KS3
- 硅基互联网医院
Quantifiable outcome
- Mean HbA1c reduction of 0.54 percentage points associated with digital therapeutics using Sibionics CGM data (4th AGP & DTx Summit 2026)
- +6 more outcomes
Companies that use SiBionics
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
SiBionics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability11 records
Feature7 records
SiBionics partnerships and signals
Strategic signalScale indicators11 records
Recent moves13 records
Expansion highlights6 records
SiBionics competitors and assessment
Company assessmentOthers
- Novo Nordisk (Digital Health Ecosystem): Novo Nordisk is both a strategic partner (NovoCare platform integration) and an adjacent player in digital diabetes management. While primarily a pharmaceutical company, its expanding digital health ecosystem competes for the same integrated diabetes management value SiBionics is building.
Regional players
- Yuyue Medical (Yuwell): Yuyue Medical is a major Chinese medical device company that has entered the CGM market and competes with SiBionics primarily in China's hospital and consumer segments, leveraging its broader medical device distribution network.
- Ascensia Diabetes Care: Ascensia (formerly Bayer Diabetes Care) offers the Contour blood glucose monitoring portfolio and competes with SiBionics in the BGM-to-CGM transition market, especially in Europe and emerging markets where CGM adoption is still being built from BGM bases.
Broad incumbents
- Roche Diabetes Care: Roche offers Accu-Chek blood glucose monitors and is expanding into digital diabetes management. While less direct in CGM, it competes with SiBionics in BGM, diabetes data platforms, and integrated diabetes care solutions, particularly in European and emerging markets.
- Medtronic (Guardian Connect / Simplera): Medtronic offers CGM systems integrated with its insulin pumps, including Guardian 4 referenced in SiBionics' pricing comparison. Both compete for hospital and Type 1 diabetic customers, though Medtronic's CGM is bundled within a broader diabetes pump ecosystem.
- Abbott (FreeStyle Libre): Abbott's FreeStyle Libre is the highest-volume CGM globally and represents SiBionics' primary mass-market competitor. Both offer factory-calibrated 14-day sensors; Abbott has the dominant global installed base and brand recognition that SiBionics must overcome internationally.
Emerging players
- Senseonics (Eversense): Senseonics makes the Eversense implantable 180-day CGM, an alternative CGM modality. While the technology approach differs (implantable vs. SiBionics' disposable sensor), it competes for the same Type 1 and insulin-dependent Type 2 patient pool.
Direct peers
- Microtech Medical: Microtech Medical is a Chinese CGM manufacturer and direct domestic competitor to SiBionics, both based in China with NMPA-approved CGM products targeting hospital and consumer segments. They are similarly positioned in price-sensitive markets and increasingly in international expansion.
- Dexcom: Dexcom is the global leader in CGM technology with G6/G7 products and direct overlap with SiBionics' GS1/GS3 CGM systems. Both target Type 1 and insulin-using Type 2 diabetics with real-time factory-calibrated sensors; SiBionics explicitly benchmarks its 30-40% pricing discount against Dexcom G7.
- Medtrum Technologies: Medtrum is a Shanghai-based CGM and insulin pump maker with overlapping products targeting diabetes self-management. It competes with SiBionics in China's hospital channel and in international emerging markets via similar pricing strategies.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
SiBionics social profiles
Digital presenceSiBionics compliance and trust
Trust signalCompliance6 records
SiBionics financial estimates
Financial estimateRevenue estimate
Valuation estimate
SiBionics leadership team
Management profileNumber of profiles
Profiles8 records
SiBionics subsidiaries and ownership
Company hierarchySubsidiaries5 records
SiBionics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors24 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SiBionics M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SiBionics
What does SiBionics do?
SiBionics develops, manufactures, and sells continuous glucose monitoring (CGM) systems using proprietary second-generation electrochemical sensor technology with metal redox polymer electron mediators. The company sells CGM sensors, reusable transmitters, hospital-wide blood glucose management platforms, AI fundus screening software (eye-si), and is commercializing the world's first continuous ketone monitoring (KS3 CKM) system, serving both individual consumers and healthcare institutions across 70+ countries.
Is SiBionics a public or private company?
SiBionics is a private company. It is classified as venture growth investor backed and is currently operating.
When was SiBionics founded?
SiBionics was founded in 2015. It employs 501 to 1,000 people.
Where is SiBionics based?
SiBionics is headquartered in Shenzhen, China, in the Asia region.
How does SiBionics make money?
Four revenue lines are on record. CGM device hardware sales are the primary driver. The others are hospital/institutional blood glucose management solutions, internet hospital and digital health services and international market sales.
Who are SiBionics's main competitors?
Novo Nordisk (Digital Health Ecosystem) is listed as an others. Regional players are Yuyue Medical (Yuwell) and Ascensia Diabetes Care. Broad incumbents are Roche Diabetes Care, Medtronic (Guardian Connect / Simplera) and Abbott (FreeStyle Libre). Senseonics (Eversense) is listed as an emerging player. Direct peers are Microtech Medical, Dexcom and Medtrum Technologies.
Does SiBionics have an API?
No public API is recorded for SiBionics.
What industry is SiBionics in?
SiBionics's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems, with a secondary code of HLAKADAA, Diabetes (General). Its NAICS code is 334510 and its SIC code is 3845.